Strauss, Gregory P.
Zamani-Esfahlani, Farnaz
Raugh, Ian M.
Luther, Lauren
Sayama, Hiroki
Funding for this research was provided by:
National Institute of Mental Health (R21- MH112925)
Article History
Received: 14 July 2022
Accepted: 22 May 2023
First Online: 6 June 2023
Declarations
:
: Dr. Gregory Strauss is one of the original developers of the Brief Negative Symptom Scale (BNSS) and receives royalties and consultation fees from Medavante-ProPhase LLC in connection with commercial use of the BNSS and other professional activities; these fees are donated to the Brain and Behavior Research Foundation. Dr. Strauss has received honoraria and travel support from Medavante-ProPhase LLC for training pharmaceutical company raters on the BNSS. In the past 2 years, Dr. Strauss has consulted for and/or been on the speaker bureau for Minerva Neurosciences, Acadia, Lundbeck, Sunovion, Boehringer Ingelheim, and Otsuka pharmaceutical companies. All other authors have no relevant disclosures to report.